LAGUNA HILLS, Calif., April 08, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment ...
A complete ablation system which includes the smallest footprint of any RF Generator and is comprised of four components: Qubic RF controller, Qubic Force Module, Qubic RF Generator and Qiona ...
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S.
Pulse Biosciences PLSE recently announced that the FDA has granted Investigational Device Exemption (“IDE”) approval to initiate its nPulse Cardiac Catheter Ablation System study for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results